[ORGANIZATION]
HOPE‑3 trial
Featured in 1 tracked story · first seen
Situations
Deramiocel DMD trial & FDA panel rejection
2 clusters · 10 sources · last updated
Latest: Capricor Therapeutics' deramiocel fails FDA advisory panel vote despite trial benefits
The FDA advisory committee voted 9‑to‑3 against recommending approval of Capricor Therapeutics’ experimental stem‑cell therapy deramiocel for Duchenne muscular dystrophy‑related cardiomyopathy, reinforcing earlier staff